19,20-EpDPE, a bioactive CYP450 metabolite of DHA monoacyglyceride, decreases Ca2+ sensitivity in human pulmonary arteries

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 4, 2011, Pages

  Morin, Caroline ^a,b   Fortin, Samuel ^a   Rousseau, Eric ^b  

^a SCF Pharma ^*  (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

19; 20 epoxydocosapentaenoic acid; Cytochrome P 450; Docosahexahenoic acid derivative; Hypertension; Pulmonary artery; Rho kinase

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 19,20 EPOXYDOCOSAPENTAENOIC ACID; BETA ESCIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL; CYTOCHROME P450; DOCOSAHEXAENOIC ACID MONOACYLGLYCERIDE; H 1152; OXYGENASE INHIBITOR; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; ENZYME ACTIVITY; FATTY ACID METABOLISM; HUMAN; HUMAN TISSUE; IC 50; ISOMETRICS; MUSCLE TONE; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; TISSUE CULTURE; WESTERN BLOTTING;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; AMIDES; BIOTRANSFORMATION; CALCIUM; CYTOCHROME P-450 ENZYME SYSTEM; DOCOSAHEXAENOIC ACIDS; EPOXY COMPOUNDS; ESCIN; FATTY ACIDS, UNSATURATED; HUMANS; ISOMETRIC CONTRACTION; MONOGLYCERIDES; MUSCLE CONTRACTION; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PULMONARY ARTERY; RHOA GTP-BINDING PROTEIN; VASOCONSTRICTOR AGENTS;

EID: 80053270465     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00380.2011     Document Type: Article

References (37)

1. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshit A. Longterm treatment with a Rho-kinase inhibitor improves monocrotalineinduced fatal pulmonary hypertension in rats. Circ Res 94: 385-393, 2004.
2. Abeywardena MY, Head RJ. Dietary polyunsaturated fatty acid and antioxidant modulation of vascular dysfunction in the spontaneously hypertensive rat. Prostaglandins Leukot Essent Fatty Acids 65: 91-97, 2001.
3. Abeywardena MY, Head RJ. Longchain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc Res 52: 361-371, 2001.
4. Arnold C, Konkel A, Fischer R, Schunck WH. Cytochrome P450- dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol Rep 62: 536-547, 2010.
5. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287: L656-L664, 2004.
6. Fer M, Dreano Y, Lucas D, Corcos L, Salaun JP, Berthou F, Amet Y. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys 471: 116-125, 2008.
7. Fortin S. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. Can Patent 2: 672 513, 2008.
8. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25: 144-149, 2010.
9. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91: 391-392, 2005.
10. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875, 2001.
11. Guibert C, Morin C, Rousseau E. Vascular and bronchial organ culture models and smooth muscle physiology. In: New Frontiers in Smooth Muscle Biology and Physiology, edited by Savineau J.-P. Kerala, India: Transworld Research Network, 2007, chapt. 3, p. 39-56.
12. Guibert C, Savineau JP, Crevel H, Marthan R, Rousseau E. Effect of short term organoid culture on pharmaco-mechanical properties of rat extra and intrapulmonary arteries. Br J Pharmacol 146: 692-701, 2005.
13. Hirafuji M, Machida T, Hamaue N, Minami M. Cardiovascular protective effects of n-3 polyunsaturated fatty acids with special emphasis on docosahexaenoic acid. J Pharm Sci 92: 308-316, 2003.
14. Humbert M, Khaltaev N, Bousquet J, Souza R. Pulmonary hypertension: from an orphan disease to a public health problem. Chest 132: 365-367, 2007.
15. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436, 2004.
16. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, Nakano T. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70: 174-178, 2006.
17. 2+-sensitization of rat pulmonary artery. Cardiovasc Res 77: 570-579, 2008.
18. Konkel A, Schunck WH. Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta 1814: 210-222, 2011.
19. Kris-Etherton PM., Harris WS., Appel LJ; Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106: 2747-2757, 2002.
20. Lauterbach B, Barbosa-Sicard E, Wang MH, Honeck H, Kargel E, Theuer J, Schwartzman ML, Haller H, Luft FC, Gollasch M, Schunck WH. Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension 39: 609-613, 2002.
21. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98: 322-334, 2006.
22. Lucas D, Goulitquer S, Marienhagen J, Fer M, Dreano Y, Schwaneberg U, Amet Y, Corcos L. Stereoselective epoxidation of the last double bond of polyunsaturated fatty acids by human cytochromes P450. J Lipid Res 51: 1125-1133, 2010.
23. Mizutani M, Asano M, Roy S, Nakajima T, Soma M, Yamashita K, Okuda Y. Omega-3 polyunsaturated fatty acids inhibit migration of human vascular smooth muscle cells in vitro. Life Sci 61: PL269-PL274, 1997.
24. Morin C, Sirois M, Echave V, Albadine R, Rousseau E. 17,18- epoxyeicosatetraenoic acid targets PPARgamma and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase. Am J Respir Cell Mol Biol 43: 564-575, 2010.
25. Morin C, Sirois M, Echave V, Rizcallah E, Rousseau E. Relaxing effects of 17(18)-EpETE on arterial and airway smooth muscles in human lung. Am J Physiol Lung Cell Mol Physiol 296: L130-L139, 2009.
26. Mouchaers KT, Schalij I, de Boer MA, Postmus PE, van Hinsbergh VW, van Nieuw Amerongen GP, Vonk Noordegraaf A, van der Laarse WJ. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J 36: 800-807, 2010.
27. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, Oka M. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171: 494-499, 2005.
28. Nagaoka T, Gebb SA, Karoor V, Homma N, Morris KG, McMurtry IF, Oka M. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol 100: 996-1002, 2006.
29. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry I, Oka M. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 287: L665-L672, 2004.
30. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 100: 923-929, 2007.
31. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185, 2002.
32. Rubin LJ. Pulmonary arterial hypertension. Proc Am Thorac Soc 3: 111-115, 2006.
33. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83: 1325-1358, 2003.
34. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, Schwartzman ML. Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284: 966-973, 1998.
35. Wang RX, Chai Q, Lu T, Lee HC. Activation of vascular BK channels by docosahexaenoic acid is dependent on cytochrome P450 epoxygenase activity. Cardiovasc Res 90: 344-352, 2011.
36. Ye D, Zhang D, Oltman C, Dellsperger K, Lee HC, VanRollins M. Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calciumactivated potassium channels. J Pharmacol Exp Ther 303: 768-776, 2002.
37. Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC, VanRollins M. EET homologs potently dilate coronary microvessels and activate BKCa channels. Am J Physiol Heart Circ Physiol 280: H2430-H2440, 2001.